Mengrui Liu

ORCID: 0009-0001-4823-0134
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Advanced Surface Polishing Techniques
  • Nanoplatforms for cancer theranostics
  • Corrosion Behavior and Inhibition
  • Extracellular vesicles in disease
  • Dendrimers and Hyperbranched Polymers
  • Nanoparticle-Based Drug Delivery
  • Advanced Drug Delivery Systems
  • Semiconductor materials and devices
  • Proteoglycans and glycosaminoglycans research
  • Tissue Engineering and Regenerative Medicine
  • Electrodeposition and Electroless Coatings
  • Inhalation and Respiratory Drug Delivery
  • Metal and Thin Film Mechanics
  • Force Microscopy Techniques and Applications
  • Nanocomposite Films for Food Packaging
  • Advancements in Transdermal Drug Delivery
  • Cardiac Structural Anomalies and Repair
  • Proteins in Food Systems
  • RNA Interference and Gene Delivery
  • Integrated Circuits and Semiconductor Failure Analysis
  • Anodic Oxide Films and Nanostructures
  • Advanced Machining and Optimization Techniques
  • Cancer Cells and Metastasis
  • Viral Infections and Immunology Research
  • Ginseng Biological Effects and Applications

Columbia University
2024-2025

Columbia University Irving Medical Center
2025

Henan University of Science and Technology
2025

North Carolina State University
2020-2022

Hebei University of Chinese Medicine
2022

Hebei University of Technology
2019-2021

University of North Carolina at Chapel Hill
2019-2021

Tianjin University of Technology
2019-2021

Shandong University
2015-2020

Chinese University of Hong Kong
2015

Stem cell therapy is a promising strategy for cardiac repair. However, clinical efficacy hampered by poor engraftment and the elusive repair mechanisms of transplanted stem cells. The lung reservoir hematopoietic cells (HSCs) major biogenesis site platelets. A sought to redirect resident injured heart therapeutic after myocardial infarction (MI). To achieve this goal, CD34-CD42b platelet-targeting bispecific antibodies (PT-BsAbs) are designed simultaneously recognize HSCs (via CD34)...

10.1002/advs.202002127 article EN cc-by Advanced Science 2020-11-19

<h3>Background</h3> Lung carcinoma is one of the most common cancers and has lowest survival rates in world. Cytokines such as interleukin-12 (IL-12) have demonstrated considerable potential robust tumour suppressors. However, their applications are limited due to off-target toxicity. <h3>Methods</h3> In this study, we develop inhalable extracellular vesicles loaded with IL-12 mRNA address lung cancer bolster systemic immunity tumor-bearing mouse models. into human embryonic kidney...

10.1136/jitc-2024-sitc2024.1117 article EN cc-by-nc Regular and Young Investigator Award Abstracts 2024-11-01

Abstract Idiopathic pulmonary fibrosis (IPF) remains an incurable form of interstitial lung disease with sub‐optimal treatments that merely address adverse symptoms or slow fibrotic progression. Here, inhalable hsa‐miR‐30a‐3p‐loaded liposomes (miR‐30a) for the treatment bleomycin‐induced in mice are presented. It was previously found exosomes (Exo) derived from spheroid cells therapeutic multiple animal models and highly enriched hsa‐miR‐30a‐3p. The present study investigates this miRNA as a...

10.1002/advs.202405434 article EN cc-by Advanced Science 2025-03-22
Coming Soon ...